The Food and Drug Administration (FDA) has approved a new treatment for inhalational anthrax.
Anthrasil, the brand name for anthrax immune globulin intravenous, should be used in combination with appropriate antibacterial drugs. It is manufactured from the plasma of people vaccinated against anthrax, which contains antibodies that neutralize toxins produced by the anthrax bacteria.
The treatment has been part of the US Strategic National Stockpile since 2011, when the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority purchased Anthrasil as an experimental drug under Project BioShield. If it had been needed before FDA approval, it would have required an emergency use authorization from the agency.
Rubin R. New Anthrax Treatment Approved. JAMA. 2015;313(17):1704. doi:10.1001/jama.2015.3713